Brown Advisory Inc. Sells 2,751 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Brown Advisory Inc. lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 0.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 895,542 shares of the company's stock after selling 2,751 shares during the quarter. Brown Advisory Inc. owned approximately 0.91% of Neurocrine Biosciences worth $99,047,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of NBIX. Vanguard Group Inc. grew its stake in shares of Neurocrine Biosciences by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company's stock valued at $1,381,331,000 after buying an additional 122,681 shares in the last quarter. Dodge & Cox lifted its holdings in Neurocrine Biosciences by 134.2% in the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock worth $411,742,000 after purchasing an additional 1,728,605 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Neurocrine Biosciences by 2.9% in the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company's stock worth $258,926,000 after purchasing an additional 53,610 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Neurocrine Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company's stock worth $255,523,000 after purchasing an additional 15,830 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Neurocrine Biosciences by 102.9% in the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock worth $198,939,000 after purchasing an additional 739,199 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insider Transactions at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 457 shares of the firm's stock in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the transaction, the insider owned 4,730 shares in the company, valued at $638,550. This trade represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jude Onyia sold 59,819 shares of the firm's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the completion of the transaction, the insider owned 18,289 shares in the company, valued at $2,385,982.94. This represents a 76.58% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,251 shares of company stock worth $14,978,602. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $1.46 during mid-day trading on Friday, reaching $133.46. The stock had a trading volume of 724,778 shares, compared to its average volume of 1,146,982. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The stock's 50-day simple moving average is $124.19 and its 200-day simple moving average is $121.53. The firm has a market capitalization of $13.21 billion, a PE ratio of 45.24, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The firm had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. During the same period last year, the business posted $1.20 EPS. The company's revenue was up 11.1% on a year-over-year basis. On average, research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

NBIX has been the subject of several analyst reports. Piper Sandler restated an "overweight" rating and issued a $154.00 target price (down from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. UBS Group upped their price target on Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a "buy" rating in a report on Wednesday. HC Wainwright cut their price target on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Needham & Company LLC upped their price target on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Finally, BMO Capital Markets upped their price target on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.